Relative Affinity of the Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase for Sialic Acid Correlates with Virus-Induced Fusion Activity

Total Page:16

File Type:pdf, Size:1020Kb

Relative Affinity of the Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase for Sialic Acid Correlates with Virus-Induced Fusion Activity JOUIRNALCOF VIROLOGY, Nov. 1993, p. 6463-6468 Vol. 67, No. 11 0022-538X/93/1 16463-06$02.00/() Copyright (© 1993, American Society for Microbiology Relative Affinity of the Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase for Sialic Acid Correlates with Virus-Induced Fusion Activity ANNE MOSCONA"2* AND RICHARD W. PELUSO3 Departments of Pediatrics,' Cell Biology/Anatomy,2 and Microbiology,3 Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, New York 10029-6574 Received 8 July 1993/Accepted 2 August 1993 The ability of enveloped viruses to cause disease depends on their ability to enter the host cell via membrane fusion events. An understanding of these early events in infection, crucial for the design of methods of blocking infection, is needed for viruses that mediate membrane fusion at neutral pH, such as paramyxoviruses and human immunodeficiency virus. Sialic acid is the receptor for the human parainfluenza virus type 3 (HPF3) hemagglutinin-neuraminidase (HN) glycoprotein, the molecule responsible for binding of the virus to cell surfaces. In order for the fusion protein (F) of HPF3 to promote membrane fusion, the HN must interact with its receptor. In the present report, two variants of HPF3 with increased fusion-promoting phenotypes were selected and used to study the function of the HN glycoprotein in membrane fusion. Increased fusogenicity correlated with single amino acid changes in the HN protein that resulted in increased binding of the variant viruses to the sialic acid receptor. These results suggest that the avidity of binding of the HN protein to its receptor regulates the level of F protein-mediated fusion and begin to define one role of the receptor-binding protein of a paramyxovirus in the membrane fusion process. Enveloped viruses have evolved mechanisms of protein- membranes despite diminished receptor availability and which mediated membrane fusion that enable them to infect their have a greatly increased ability to fuse cells under normal hosts; these strategies have begun to shed light on membrane conditions are selected. These variants offer a new approach to fusion mechanisms utilized by cells (2). The envelope of the the study of the mechanism of paramyxovirus-induced cell paramyxovirus human parainfluenza virus type 3 (HPF3) con- fusion and the role of the HN protein in this process. tains two viral glycoproteins, the hemagglutinin-neuraminidase (HN) and the fusion protein (F). The HN glycoprotein binds to sialic acid-containing receptor molecules on the cell surface to MATERIALS AND METHODS initiate infection (24). Fusion of the viral envelope with the cell's plasma membrane is mediated by the F glycoprotein and Virus and cells. CV-1 cells were grown in monolayers in occurs at neutral pH at the cell surface, without a requirement Eagle's minimal essential medium supplemented with 10% for an acid-mediated conformational change of the fusion fetal bovine serum. Stocks of wt HPF3 were made in CV-1 cells molecule (8, 21, 25). This feature distinguishes paramyxovi- from virus that was plaque purified four times. Virus titer was ruses from viruses, such as influenza virus, that require a low determined by a plaque assay with CV-1 cells. Cells were pH to mediate fusion (reviewed in reference 13). Infection infected by aspirating the medium, washing the monolayers results in fusion between adjacent cells, which involves the with medium lacking serum, and then adding medium lacking interaction of F protein, expressed on the surface of an serum with various amounts of wt or C variant HPF3 to the infected cell, with the membrane of an adjacent uninfected cells, as described in the text. After incubation at 37°C for 60 cell. min, the medium was aspirated; either medium lacking serum We have reported that the HN glycoprotein is essential for or agar overlay medium was added. Cells were photographed cell fusion mediated by HPF3 and that interaction of HN with through a phase-contrast microscope. its receptor is required in order for F to promote membrane Neuraminidase treatment. Monolayer cultures of infected fusion during viral infection (18). We now report that the cells were treated with neuraminidase (from Clostridium per- avidity of binding of virus to the sialic acid receptor correlates fringens; Sigma Chemical Co., St. Louis, Mo.) by washing the with the level of F protein-mediated fusion. cells with medium lacking serum and then adding serum-free medium neuraminidase to the cells Syncytium formation by wild-type (wt) HPF3 can be pre- containing (19). Isolation of HPF3 variants. cultures of CV-1 vented in a low-multiplicity infection by the addition of neura- Monolayer cells in 60-mm dishes were infected with HPF3 and treated minidase to the cells; by removing some cell surface sialic acid receptors, the neuraminidase treatment prevents the requisite with 0.1 U of C. perfringens neuraminidase as described interaction of the wt viral HN glycoprotein with its receptor previously (19). Supernatant fluid from these infected cultures (19). While the neuraminidase-treated infected cells do not was collected and used in plaque assays. Large plaques were fuse, the viral infection spreads throughout the culture, and all picked and plaque purified twice, and a single plaque was used the cells become persistently infected (19, 20). Under these to infect each CV-1 cell monolayer for preparation of stocks of variant viruses. conditions, variant viruses which are able to fuse with cell Protein analysis. 35S-radiolabeled virus proteins were pre- pared as previously described (17). At 3, 6, or 9 h after infection with either wt or C variant HPF3, CV-1 cell mono- * Corresponding author. layers were cultured for 15 min in methionine-free minimal 6463 6464 MOSCONA AND PELUSO J. VIROL. wt C-O C-22 plaque assay 24 hrs * X v~~~~~~~~~/1S , ,g a @.; ? se: ¼B plaque " 'A:#b; assay i22t ''::¾?1?Jh^}? 24 hrs * *..,?sS# ......;.s... ,., 3 X'iLS..i....'S infected monolayer (moi=0.1) 18 hrs p.i. FIG. 1. Fusion properties of HPF3 variants. CV-1 cell cultures and HPF3 were grown as described in Materials and Methods. Confluent cell monolayers were infected with either wt HPF3 or C variant HPF3 at an MOI of 0.1 PFU/cell. For observation of plaques, overlay medium was prepared and added after a 90-min adsorption period. The photographs show the plaque size and morphology and the extent of CPE in a monolayer at 1 day postinfection (p.i.). essential medium and then for 1 h in methionine-free minimal was then added to each well. The plates were photographed 90 essential medium containing [35S]methionine (50 ,xCi/ml). min after the addition of erythrocytes. Mock-infected cell proteins were prepared in parallel with the Sequence analysis. The F and HN genes of C variant viruses infected cell proteins at each time point. were sequenced after reverse transcription-polymerase chain Assays of viral neuraminidase. Neuraminidase activities, reaction (PCR) amplification of each gene, either by direct substrate specificities, and pH optima were determined for wt sequencing of the PCR product or by cloning into pUC19 and HPF3 and C variants by the thiobarbituric acid assay (14). 2,3- subsequent dideoxy sequencing of plasmid DNA. Total RNA and 2,6-neuraminyllactose substrates were purchased from from infected cells was prepared as described previously (17). Sigma Chemical Co. The primers used for the reverse transcriptase reaction were Hemagglutination inhibition assays. Hemagglutination in- complementary to the 3'-terminal 19 nucleotides of the F gene hibition assays were performed at 4°C (22) with fetal calf mRNA sequence (5) and the 3' 32 nucleotides of the HN gene serum (FCS) or bovine fetuin as the competitor. Four hemag- mRNA sequence (27). The upstream primers used for PCR glutination units of virus in 50 il was added to each dilution of amplification corresponded to the 5'-terminal 15 nucleotides FCS (in 50 pul of phosphate-buffered saline [PBS]) or to of the F gene mRNA sequence and the 5'-terminal 16 nucle- dilutions of fetuin in the wells of a microtiter plate. Fifty otides of the HN mRNA sequence. Primers for sequencing microliters of a 0.5% suspension of human erythrocytes in PBS were synthesized to be complementary to the F or HN gene VOL. 67, 1993 HUMAN PARAINFLUENZA VIRUS TYPE 3 MEMBRANE FUSION 6465 wt C-O C-22 HPF3 alone + neuraminidase HPF3 alone + neuraminidase HPF3 alone + neuraminidase low moi ( 01) FIG. 2. Effect of MOI and of neuraminidase addition on CPE produced by HPF3 variants. Monolayer cultures of CV-1 cells were infected with wt or C variant HPF3 at either a low MOI (0.01 PFU/cell) or a high MOI (5 PFU/cell). For each virus, the cells were either infected with virus alone or received 0.1 U of C. perfringens neuraminidase after viral infection, as described in Materials and Methods. The photographs show CPE 1 day after infection. In cells infected with C variant HPF3, infection at a high MOI did not block fusion; the CPE in these cells is equivalent to that in those infected at a low MOI. In addition, in cells infected with variant HPF3, exogenous neuraminidase addition did not prevent cell fusion. sequence at 200-bp intervals. Sequence alterations were con- effect of neuraminidase on cell fusion and are able to fuse firmed by repeating at least twice the RNA isolation from efficiently under conditions of decreased receptor availability. infected cells, reverse transcription-PCR amplification, and We determined whether the variant fusion phenotype could sequencing of the altered region. be explained by altered growth characteristics of the virus. Figure 3 shows that the growth characteristics of the variant RESULTS viruses do not differ from those of the wt.
Recommended publications
  • Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza a Viruses
    viruses Review Emerging Role of Mucosal Vaccine in Preventing Infection with Avian Influenza A Viruses Tong Wang 1, Fanhua Wei 2 and Jinhua Liu 1,* 1 Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China; [email protected] 2 College of Agriculture, Ningxia University, Yinchuan 750021, China; [email protected] * Correspondence: [email protected] Received: 22 July 2020; Accepted: 5 August 2020; Published: 7 August 2020 Abstract: Avian influenza A viruses (AIVs), as a zoonotic agent, dramatically impacts public health and the poultry industry. Although low pathogenic avian influenza virus (LPAIV) incidence and mortality are relatively low, the infected hosts can act as a virus carrier and provide a resource pool for reassortant influenza viruses. At present, vaccination is the most effective way to eradicate AIVs from commercial poultry. The inactivated vaccines can only stimulate humoral immunity, rather than cellular and mucosal immune responses, while failing to effectively inhibit the replication and spread of AIVs in the flock. In recent years, significant progresses have been made in the understanding of the mechanisms underlying the vaccine antigen activities at the mucosal surfaces and the development of safe and efficacious mucosal vaccines that mimic the natural infection route and cut off the AIVs infection route. Here, we discussed the current status and advancement on mucosal immunity, the means of establishing mucosal immunity, and finally a perspective for design of AIVs mucosal vaccines. Hopefully, this review will help to not only understand and predict AIVs infection characteristics in birds but also extrapolate them for distinction or applicability in mammals, including humans.
    [Show full text]
  • Symposium on Viral Membrane Proteins
    Viral Membrane Proteins ‐ Shanghai 2011 交叉学科论坛 Symposium for Advanced Studies 第二十七期:病毒离子通道蛋白的结构与功能研讨会 Symposium on Viral Membrane Proteins 主办单位:中国科学院上海交叉学科研究中心 承办单位:上海巴斯德研究所 1 Viral Membrane Proteins ‐ Shanghai 2011 Symposium on Viral Membrane Proteins Shanghai Institute for Advanced Studies, CAS Institut Pasteur of Shanghai,CAS 30.11. – 2.12 2011 Shanghai, China 2 Viral Membrane Proteins ‐ Shanghai 2011 Schedule: Wednesday, 30th of November 2011 Morning Arrival Thursday, 1st of December 2011 8:00 Arrival 9:00 Welcome Bing Sun, Co-Director, Pasteur Institute Shanghai 9: 10 – 9:35 Bing Sun, Pasteur Institute Shanghai Ion channel study and drug target fuction research of coronavirus 3a like protein. 9:35 – 10:00 Tim Cross, Tallahassee, USA The proton conducting mechanism and structure of M2 proton channel in lipid bilayers. 10:00 – 10:25 Shy Arkin, Jerusalem, IL A backbone structure of SARS Coronavirus E protein based on Isotope edited FTIR, X-ray reflectivity and biochemical analysis. 10:20 – 10:45 Coffee Break 10:45 – 11:10 Rainer Fink, Heidelberg, DE Elektromechanical coupling in muscle: a viral target? 11:10 – 11:35 Yechiel Shai, Rehovot, IL The interplay between HIV1 fusion peptide, the transmembrane domain and the T-cell receptor in immunosuppression. 11:35 – 12:00 Christoph Cremer, Mainz and Heidelberg University, DE Super-resolution Fluorescence imaging of cellular and viral nanostructures. 12:00 – 13:30 Lunch Break 3 Viral Membrane Proteins ‐ Shanghai 2011 13:30 – 13:55 Jung-Hsin Lin, National Taiwan University Robust Scoring Functions for Protein-Ligand Interactions with Quantum Chemical Charge Models. 13:55 – 14:20 Martin Ulmschneider, Irvine, USA Towards in-silico assembly of viral channels: the trials and tribulations of Influenza M2 tetramerization.
    [Show full text]
  • A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures
    viruses Communication A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures Ryan P. Bennett 1,† , Courtney L. Finch 2,† , Elena N. Postnikova 2 , Ryan A. Stewart 1, Yingyun Cai 2 , Shuiqing Yu 2 , Janie Liang 2, Julie Dyall 2 , Jason D. Salter 1 , Harold C. Smith 1,* and Jens H. Kuhn 2,* 1 OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623, USA; [email protected] (R.P.B.); [email protected] (R.A.S.); [email protected] (J.D.S.) 2 NIH/NIAID/DCR/Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA; courtney.fi[email protected] (C.L.F.); [email protected] (E.N.P.); [email protected] (Y.C.); [email protected] (S.Y.); [email protected] (J.L.); [email protected] (J.D.) * Correspondence: [email protected] (H.C.S.); [email protected] (J.H.K.); Tel.: +1-585-697-4351 (H.C.S.); +1-301-631-7245 (J.H.K.) † These authors contributed equally to this work. Abstract: Filoviruses, such as Ebola virus and Marburg virus, are of significant human health concern. From 2013 to 2016, Ebola virus caused 11,323 fatalities in Western Africa. Since 2018, two Ebola virus disease outbreaks in the Democratic Republic of the Congo resulted in 2354 fatalities. Although there is progress in medical countermeasure (MCM) development (in particular, vaccines and antibody- based therapeutics), the need for efficacious small-molecule therapeutics remains unmet. Here we describe a novel high-throughput screening assay to identify inhibitors of Ebola virus VP40 matrix protein association with viral particle assembly sites on the interior of the host cell plasma membrane.
    [Show full text]
  • Development and Effects of Influenza Antiviral Drugs
    molecules Review Development and Effects of Influenza Antiviral Drugs Hang Yin, Ning Jiang, Wenhao Shi, Xiaojuan Chi, Sairu Liu, Ji-Long Chen and Song Wang * Key Laboratory of Fujian-Taiwan Animal Pathogen Biology, College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou 350002, China; [email protected] (H.Y.); [email protected] (N.J.); [email protected] (W.S.); [email protected] (X.C.); [email protected] (S.L.); [email protected] (J.-L.C.) * Correspondence: [email protected] Abstract: Influenza virus is a highly contagious zoonotic respiratory disease that causes seasonal out- breaks each year and unpredictable pandemics occasionally with high morbidity and mortality rates, posing a great threat to public health worldwide. Besides the limited effect of vaccines, the problem is exacerbated by the lack of drugs with strong antiviral activity against all flu strains. Currently, there are two classes of antiviral drugs available that are chemosynthetic and approved against influenza A virus for prophylactic and therapeutic treatment, but the appearance of drug-resistant virus strains is a serious issue that strikes at the core of influenza control. There is therefore an urgent need to develop new antiviral drugs. Many reports have shown that the development of novel bioactive plant extracts and microbial extracts has significant advantages in influenza treat- ment. This paper comprehensively reviews the development and effects of chemosynthetic drugs, plant extracts, and microbial extracts with influenza antiviral activity, hoping to provide some refer- ences for novel antiviral drug design and promising alternative candidates for further anti-influenza drug development.
    [Show full text]
  • Lentivirus and Lentiviral Vectors Fact Sheet
    Lentivirus and Lentiviral Vectors Family: Retroviridae Genus: Lentivirus Enveloped Size: ~ 80 - 120 nm in diameter Genome: Two copies of positive-sense ssRNA inside a conical capsid Risk Group: 2 Lentivirus Characteristics Lentivirus (lente-, latin for “slow”) is a group of retroviruses characterized for a long incubation period. They are classified into five serogroups according to the vertebrate hosts they infect: bovine, equine, feline, ovine/caprine and primate. Some examples of lentiviruses are Human (HIV), Simian (SIV) and Feline (FIV) Immunodeficiency Viruses. Lentiviruses can deliver large amounts of genetic information into the DNA of host cells and can integrate in both dividing and non- dividing cells. The viral genome is passed onto daughter cells during division, making it one of the most efficient gene delivery vectors. Most lentiviral vectors are based on the Human Immunodeficiency Virus (HIV), which will be used as a model of lentiviral vector in this fact sheet. Structure of the HIV Virus The structure of HIV is different from that of other retroviruses. HIV is roughly spherical with a diameter of ~120 nm. HIV is composed of two copies of positive ssRNA that code for nine genes enclosed by a conical capsid containing 2,000 copies of the p24 protein. The ssRNA is tightly bound to nucleocapsid proteins, p7, and enzymes needed for the development of the virion: reverse transcriptase (RT), proteases (PR), ribonuclease and integrase (IN). A matrix composed of p17 surrounds the capsid ensuring the integrity of the virion. This, in turn, is surrounded by an envelope composed of two layers of phospholipids taken from the membrane of a human cell when a newly formed virus particle buds from the cell.
    [Show full text]
  • Virus-Host Interactomics: New Insights and Opportunities for Antiviral Drug Discovery
    de Chassey et al. Genome Medicine 2014, 6:115 http://genomemedicine.com/content/6/11/115 REVIEW Virus-host interactomics: new insights and opportunities for antiviral drug discovery Benoît de Chassey1, Laurène Meyniel-Schicklin1, Jacky Vonderscher1, Patrice André2,3,4 and Vincent Lotteau3,4* Abstract The current therapeutic arsenal against viral infections remains limited, with often poor efficacy and incomplete coverage, and appears inadequate to face the emergence of drug resistance. Our understanding of viral biology and pathophysiology and our ability to develop a more effective antiviral arsenal would greatly benefit from a more comprehensive picture of the events that lead to viral replication and associated symptoms. Towards this goal, the construction of virus-host interactomes is instrumental, mainly relying on the assumption that a viral infection at the cellular level can be viewed as a number of perturbations introduced into the host protein network when viral proteins make new connections and disrupt existing ones. Here, we review advances in interactomic approaches for viral infections, focusing on high-throughput screening (HTS) technologies and on the generation of high-quality datasets. We show how these are already beginning to offer intriguing perspectives in terms of virus-host cell biology and the control of cellular functions, and we conclude by offering a summary of the current situation regarding the potential development of host-oriented antiviral therapeutics. Introduction the virus life-cycle. These proteins
    [Show full text]
  • Influenza Virus M2 Protein Ion Channel Activity Helps to Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence Durin
    Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface Esmeralda Alvarado-Facundo,a,b Yamei Gao,a Rosa María Ribas-Aparicio,b Alicia Jiménez-Alberto,b Carol D. Weiss,a Wei Wanga Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USAa; Departamento de Microbiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexicob ABSTRACT The influenza virus hemagglutinin (HA) envelope protein mediates virus entry by first binding to cell surface receptors and then fusing viral and endosomal membranes during endocytosis. Cleavage of the HA precursor (HA0) into a surface receptor-binding Downloaded from subunit (HA1) and a fusion-inducing transmembrane subunit (HA2) by host cell enzymes primes HA for fusion competence by repositioning the fusion peptide to the newly created N terminus of HA2. We previously reported that the influenza virus M2 protein enhances pandemic 2009 influenza A virus [(H1N1)pdm09] HA-pseudovirus infectivity, but the mechanism was unclear. In this study, using cell-cell fusion and HA-pseudovirus infectivity assays, we found that the ion channel function of M2 was re- quired for enhancement of HA fusion and HA-pseudovirus infectivity. The M2 activity was needed only during HA biosynthesis, and proteolysis experiments indicated that M2 proton channel activity helped to protect (H1N1)pdm09 HA from premature conformational changes as it traversed low-pH compartments during transport to the cell surface. While M2 has previously been shown to protect avian influenza virus HA proteins of the H5 and H7 subtypes that have polybasic cleavage motifs, this study demonstrates that M2 can protect HA proteins from human H1N1 strains that lack a polybasic cleavage motif.
    [Show full text]
  • HIV-1) CD4 Receptor and Its Central Role in Promotion of HIV-1 Infection
    MICROBIOLOGICAL REVIEWS, Mar. 1995, p. 63–93 Vol. 59, No. 1 0146-0749/95/$04.0010 Copyright q 1995, American Society for Microbiology The Human Immunodeficiency Virus Type 1 (HIV-1) CD4 Receptor and Its Central Role in Promotion of HIV-1 Infection STEPHANE BOUR,* ROMAS GELEZIUNAS,† AND MARK A. WAINBERG* McGill AIDS Centre, Lady Davis Institute-Jewish General Hospital, and Departments of Microbiology and Medicine, McGill University, Montreal, Quebec, Canada H3T 1E2 INTRODUCTION .........................................................................................................................................................63 RETROVIRAL RECEPTORS .....................................................................................................................................64 Receptors for Animal Retroviruses ........................................................................................................................64 CD4 Is the Major Receptor for HIV-1 Infection..................................................................................................65 ROLE OF THE CD4 CORECEPTOR IN T-CELL ACTIVATION........................................................................65 Structural Features of the CD4 Coreceptor..........................................................................................................65 Interactions of CD4 with Class II MHC Determinants ......................................................................................66 CD4–T-Cell Receptor Interactions during T-Cell Activation
    [Show full text]
  • Localization of Membrane Permeabilization and Receptor Binding Sites on the VP4 Hemagglutinin of Rotavirus: Implications for Cell Entry
    doi:10.1006/jmbi.2001.5238 available online at http://www.idealibrary.com on J. Mol. Biol. (2001) 314, 985±992 Localization of Membrane Permeabilization and Receptor Binding Sites on the VP4 Hemagglutinin of Rotavirus: Implications for Cell Entry Mariana Tihova1, Kelly A. Dryden1, A. Richard Bellamy2 Harry B. Greenberg3 and Mark Yeager1,4* 1The Scripps Research Institute The surface of rotavirus is decorated with 60 spike-like projections, each Departments of Cell and composed of a dimer of VP4, the viral hemagglutinin. Trypsin cleavage Molecular Biology, 10550 N. of VP4 generates two fragments, VP8*, which binds sialic acid (SA), and Torrey Pines Rd., La Jolla VP5*, containing an integrin binding motif and a hydrophobic region CA 92037, USA that permeabilizes membranes and is homologous to fusion domains. Although the mechanism for cell entry by this non-enveloped virus is 2Biochemistry and Molecular unclear, it is known that trypsin cleavage enhances viral infectivity and Biology, School of Biological facilitates viral entry. We used electron cryo-microscopy and difference Sciences, University of map analysis to localize the binding sites for two neutralizing mono- Auckland, Private Bag clonal antibodies, 7A12 and 2G4, which are directed against the SA-bind- Auckland, New Zealand ing site within VP8* and the membrane permeabilization domain within 3Departments of Medicine and VP5*, respectively. Fab 7A12 binds at the tips of the dimeric heads of Microbiology and Immunology VP4, and 2G4 binds in the cleft between the two heads of the spike. Stanford University Medical When these binding results are combined with secondary structure anal- Center, 300 Pasteur Drive ysis, we predict that the VP4 heads are composed primarily of b-sheets Stanford, CA 94305, USA in VP8* and that VP5* forms the body and base primarily in b-structure 4 and a-helical conformations, respectively.
    [Show full text]
  • To Download a Copy of Agencyiq's COVID-19 Development Tracker
    Development tracker: The drugs and vaccines in development for COVID-19 The pharmaceutical and biopharmaceutical industry is scrambling to put products into development to potentially treat, cure or prevent COVID-19 infections. Based on a review by AgencyIQ of ClinicalTrials.gov, company announcements and media reports, there are at least 140 medical product candidates in various stages of testing to assess their potential effects against COVID-19 or SARS-CoV-2, the virus which causes the condition. Some have already been approved and are being assessed for their potential to treat COVID, while others are being repurposed from other late-stage development pipelines. Others are still in the very early stages of development and have not yet been tested in humans. Based on evidence from recent studies, the chances of clinical success are low. Of all drugs for infectious diseases that enter Phase 1 testing, just 26.7% go on to obtain approval. Just 31.6% of vaccines that enter Phase 1 testing go on to obtain approval. The size of the development pipeline and interest in COVID-19 may indicate that several of these products will go on to obtain approval, but the safety and efficacy of these products is far from guaranteed. As companies try to bring whatever compounds they have into clinical testing, it’s possible that few, if any, of these products will ultimately prove safe or effective. Highlights: 95+ 45+ 24+ 40+ Therapeutic medical Vaccines in development Products already approved Products already in clinical products in development for other indications development (6 vaccines, 34 therapies) Last updated 8 April 2020.
    [Show full text]
  • An Investigation of the Mechanisms Underlying HIV-1-Mediated Inflammasome Activation
    An investigation of the mechanisms underlying HIV-1-mediated inflammasome activation Christopher JK Ward Doctorate of Philosophy in Medicine Supervised by Dr. Martha Triantafilou & Prof. Kathy Triantafilou Submitted July 2017 i DECLARATION This work has not been submitted in substance for any other degree or award at this or any other university or place of learning, nor is being submitted concurrently in candidature for any degree or other award. Signed ……………………………………………………… (candidate) Date 01.07.2017 STATEMENT 1 This thesis is being submitted in partial fulfilment of the requirements for the degree of Doctorate of Philosophy (Medicine) Signed ………………………………………….…………… (candidate) Date 01.07.2017 STATEMENT 2 This thesis is the result of my own independent work/investigation, except where otherwise stated, and the thesis has not been edited by a third party beyond what is permitted by Cardiff University’s Policy on the Use of Third Party Editors by Research Degree Students. Other sources are acknowledged by explicit references. The views expressed are my own. Signed ……………………………………….……….…… (candidate) Date 01.07.2017 STATEMENT 3 I hereby give consent for my thesis, if accepted, to be available online in the University’s Open Access repository and for inter-library loan, and for the title and summary to be made available to outside organisations. Signed ……………………………………………..…..….. (candidate) Date 01.07.2017 ii Table of Contents Table of Contents ...........................................................................................................
    [Show full text]
  • Structure and Dynamics of Influenza M2 Proton Channels from Solid-State NMR By
    Structure and Dynamics of Influenza M2 Proton Channels from Solid-State NMR by Venkata Shiva Mandala B.A. Biochemistry Oberlin College, 2015 Submitted to the Department of Chemistry in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY at the MASSACHUSETTS INSTITUTE OF TECHNOLOGY February 2021 ©2020 Massachusetts Institute of Technology. All rights reserved. Signature of Author _____________________________________________________________ Department of Chemistry September 28, 2020 Certified by ____________________________________________________________________ Mei Hong Professor of Chemistry Thesis Supervisor Accepted by ___________________________________________________________________ Adam P. Willard Associate Professor of Chemistry Graduate Officer This doctoral thesis has been examined by a committee of professors from the Department of Chemistry as follows: ______________________________________________________________________________ Matthew D. Shoulders Whitehead Career Development Associate Professor Thesis Committee Chair ______________________________________________________________________________ Mei Hong Professor of Chemistry Thesis Supervisor ______________________________________________________________________________ Robert G. Griffin Arthur Amos Noyes Professor of Chemistry Thesis Committee Member 2 Structure and Dynamics of Influenza M2 Proton Channels from Solid-State NMR by Venkata Shiva Mandala Submitted to the Department of Chemistry on October 9, 2020 in Partial Fulfillment of the
    [Show full text]